Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bio-Rad Laboratories (NY: BIO )

294.04 -1.69 (-0.57%)
Streaming Delayed Price Updated: 2:49 PM EDT, May 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 85,095
Open 296.00
Bid (Size) 293.98 (1)
Ask (Size) 294.26 (4)
Prev. Close 295.73
Today's Range 290.86 - 296.00
52wk Range 261.59 - 431.79
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Analyst Landscape: 4 Takes On Bio-Rad Laboratories
Via Benzinga
BIO Stock Earnings: Bio-Rad Laboratories Beats EPS, Misses Revenue for Q1 2024
BIO stock results show that Bio-Rad Laboratories beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
-10.35%
-10.35%
1 Month
+0.44%
+0.44%
3 Month
-10.55%
-10.55%
6 Month
-3.44%
-3.44%
1 Year
-22.71%
-22.71%

More News

Read More
Bio-Rad Reports First-Quarter 2024 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad’s Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad Laboratories: Q4 Earnings Insights
Via Benzinga
Earnings Scheduled For February 15, 2024
Via Benzinga
Preview: Bio-Rad Laboratories's Earnings
Via Benzinga
Earnings Outlook For Bio-Rad Laboratories
Via Benzinga
Bio-Rad Announces Life Science Group Management Changes
From Bio-Rad Laboratories, Inc.
Via Business Wire
96% Of S&P 500 Stocks Show Upside Potential Vs. Street Estimates: Which Offers The Best Opportunity?
Via Benzinga
Topics Stocks
Exposures US Equities
Bio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad’s Chief Operating Officer Andrew Last to Retire
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad Appoints Roop K. Lakkaraju Executive Vice President, Chief Financial Officer
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad to Participate in Fireside Chat During Citi's 2024 Unplugged Medtech and Life Sciences Access Day
From Bio-Rad Laboratories, Inc.
Via Business Wire
Tech Stocks Ease On Hot PPI, Yields Rise, Microsoft, Amazon Snap 5-Week Positive Streak: What's Driving Markets Friday?
Via Benzinga
Topics Economy
Exposures Interest Rates
Applied Materials Posts Upbeat Earnings, Joins Texas Roadhouse, Vulcan Materials And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Bio-Rad Reports Fourth-Quarter and Full-Year 2023 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024
From Bio-Rad Laboratories, Inc.
Via Business Wire
10 S&P 500 Stocks With Over 40% Upside Potential: Hidden Gems Or Value Traps?
Via Benzinga
Topics Artificial Intelligence Economy Stocks
Exposures Artificial Intelligence Interest Rates US Equities
Bio-Rad’s Management to Host Investor Meetings at J.P. Morgan’s 42nd Annual Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
S&P 500's Hidden Gems: 27 Stocks With 30%+ Upside Potential According To Wall Street Analysts Targets
Via Benzinga
Topics Stocks
Exposures US Equities
Black Friday On Wall Street: 10 S&P 500 Stocks Trading At 40%+ Discount From Analysts' Expectations
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Clinical Diagnostic-Focused Bio-Rad Stock Trading Lower Today?
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Bio-Rad Reports Third-Quarter 2023 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.